Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sorry. Your opinion. I get powder because I run successful businesses.
Stock market opens at 9:30 am EDT on Monday.
There's your chance...
Because you sold some right before/during the CC in the .20-.21 range because you don't believe in Elite.
The gap stands at .1430. Very few people will get the chance to buy there. I like to put an order at .1485 and hopefully I get some shares on the gap fill. I will also buy shares at a higher price, I feel .16-.17 is a good place to get shares. I have a lot of powder and I also want to be as smart as possible on buying more. Also, and positive or game changing announcements, will change my views. Have a good weekend
GLTU.
Hi CMDawg, I like to ad more to my shares. What Gap are you seeing that needs to be filled? Is it around 0.14 or 0.16? Obviously I would like to be able to buy more shares if possible
Same old story. You get burn every time. The way I look at it, we have plenty of time to get the gap. If we don’t, that’s ok too. I am loaded with shares and ready to buy a lot more.
Lol...
.18624 (+.94%)
Staggering numbers King and the and the stock prices loses -10%+. I don't get it/ I forgot it's manipulated.
Might as well put this account of yours on ignore as well.
FY2023 Q4 vs FY2024 Q4
Revenue: +107.71%
Net income: +370.56%
Net profit margin: +230.31%
Operating income: +4062.70% (😱)
Not what I said. You are now on mute.
And yet that was years ago before profitability and growth where we are today.
Gee, I wonder who provided evidence months ago that Prasco staggered the launch and that it wouldn't be until FY2025 Q2 until we get a 100% Elite/Burel Adderall product from Prasco.....🤔
Yeah, maybe we should end the Prasco partnership.
Good grief...
Exactly.
Step 1: Undercut the competition and get into every pharmacy imaginable.
Step 2: Keep doing Step 1 until it puts your competition out of business.
Step 3: Slowly raise prices back up again.
Stock hovered around .40 for a long time when Carter said it was Elite's lowest possible valuation.
It seems that Jimmy is on call today
LOL
From the way he worded it, Q1 may be less than Q4, but he didn’t want to have that dialogue and focus more on Q4. This is sort of implied in his cautious FY25 outlook as well with soft Q1 and pick up steam throughout year with what we have now for $70M target. It also may signify that he may not be expecting much from Prasco relationship.
Looking forward to the back half of the year. Next month’s cc will provide additional insight on growth with Prasco since they started selling 4/5, basically the full Q.
I’d expect rate to be further compressed with Prasco volume growth as Inwoildnt expect it to be as profitable as our own line. Would love to see otherwise.
Margin dollar growth is always great to see. Margin rate movement often shows insights into competitive landscape.
I think we are entering an interesting accelerated phase - read here why:
For the day traders among us, they will be hit by multiple strikes from Elite - it will not be anymore the 3 to 4 months wait between PR to PR...
The stock will be much more volatile in the near future. We have two approved ANDA's that have not been launched yet, 3 drugs that we bought back that are going to be manufactured and launched, 3 ANDA's that will be approved soon (of which are 2 needle movers), and new ANDA's that will be submitted. All the above are material events that should happen in the next 6 months... So my recommendation is remain long and add up more because this puppy is gonna fly soon.
ELTP Catalyst
X 1. Cash Flow Positive - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million IMS market Approved and Launched
X 4. Adderall XR $1.56 Billion IMS market Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement - January 1st 2024
X 8. First shipment Adderall XR to Prasco Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
X 12. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__13. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
X 14. Vigabatrin Approval $233 Million
X 15. Pyros Vigabatrin -settle VigPoder trade mark challenge then LAUNCH
X 16. Generic Methotrexate Approval- Antimetabolite $42 Million
X 17. $50+ million in yearly revenues
X 18. Lowest PE ratio for OTC Healthcare sector
X 19. Become the ONLY company showing rapid growth on the OTC while being profitable
__20. Generate revenues over $20 million/quarter
__21. Double output of manufacturing and packaging facilities
__22. Generic OxyContin Approval - FIRST TO FILE Aug 17, 2023 $720 Million
__23. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
__24. Launch Tylenol with codeine $45 Million
__25. Launch generic Norco - hydrocodone acetaminophen IMS $477 Million
__26. Launch generic Percocet - oxycodone acetaminophen IMS $500 Million
__27. Launch generic Dolophine - methadone HCL tablets IMS $30 Million
__28. European distribution - Dexcel partnership approval by Israeli Health
__29. Full ownership of Adderall IR $ 335 Million
__30. Full ownership of Adderall XR $ 1.56 Billion
__31. Generic Concerta- $1.2 BILLION FDA submission
__32. $100 million in yearly revenue
__33. Generic Vyvanse Approval and Launch
__34. $200 million in yearly revenue
__35. Deep pocket partner for SequestOx
__36. Patented Unique ADF (w/o naltrexone) drug C in SequestOx trial
__37. Mikah ANDA(s)
__38. Undisclosed ANDAs/NDAs
__39. Generic Concerta Approval and Launch
__40. DollarLand PPS
__41. Big Pharma bid
__42. UpList to the NASDAQ Exchange
__43. ELTP Elite Pharmaceutical Buyout - 2 1/2 years or less from Feb 2024
__44. Vegas Baby !!!!!!!
Bullish
I think earnings will beat last quarter. Your thoughts?
Does it really matter? Look at the headlines, revenues up but margins are down. Then it tells you the margin are down because efficiency in higher volume production. Give me a break or give ELTP a break.
He did give some insights, he was also careful.
Roughly he said we are going up...
The how high has too many variables to be precise...
He should play the guessing game with us lol
"Last year's revenues were $34 million. Our goal for the current fiscal year was $40 million. Then I think around November, I modified the number to north of $40 million. And in February, we thought, okay, we're going to hit $50 million, and we ended up with $56 million. Well, that's embarrassing.
But I've learned from my mistakes, Therefore, I am not going to say that this year, our revenues are going to be $60 million. And then in November, I'll tell you we're going to go north of $60 million and February, Ops we're going to hit $70 million. I'm just going to skip all of that right now and go straight for skipping the 60s, I'm predicting that we're going to hit a minimum of $70 million for the fiscal year ending March 2025. You are not sitting in the room, but Carter just hinted, and I think maybe Nasrat hinted too.
However, that is the least I can expect on the current run rate. I have no doubt and no issues we're going to achieve that. What I think will happen is that some of you will start calling Dianne now and saying, well, he said $70 million, does that mean in November, he's going to say we're going to be north of $70 million, and then by February, he's going to say we're going to skip to $80 million? That is not what I'm saying. But if that happened, it would be embarrassing.
Not long ago, our income was in the single digits, $7 million. Then we graduated to the teens, 20s, 30s, we skipped the 40s and now we're in the 50s, and we're going to give skip to 70s and go into 60, that's all because of our sales and distribution and the excellent pipeline we have been working very hard on over the years."
And late rhe said: "Regarding the research and development pipeline, Elite has three ANDAs filed under FDA review. A generic dopamine agonist ANDA for the treatment of Parkinson's disease and ANDA for the treatment of pain management, we have already disclosed its OxyContins, a generic, a central nervous system stimulus ANDA used for attention deficit disorder. Two out of these three are needle movers and approval of one of them would have a huge impact on our revenues for next year. That's when we'll talk about skipping the 70s."
Next earnings call is 40 days away. Was it interesting that Nasrat didn’t give any insight to next qtr earnings? He should have had the data already.
I think earnings will beat last quarter. Your thoughts?
How much do they pay you to talk down the price of ELTP?
I believe the margin rate went down from 49 to 47 but its revenue grew tremendously. If they can go from 56 mil to 100 mil in FY2025 and margin rate is 45, I'll take it. That means more drugs were produced and different drugs were produced and sold.
Hey NAS, did were you able to check any of the catalysts off the list after the CC?
Thanks
You missed the importance of margin rate deterioration and a flat forecast to Q4 to the share price.
A valuation doesn’t signify a trading price. Look at the last valuation.
do you mean meeehehheheheheheee?
lol .02, .03, .04, .05, .06, 07, .08, .10, .14, .15, .16, .18 teeheeteeheeteehee 🙊
Im topin' off till next CC
Thank you mrwrn for both your posts with BE and FDA filing announcements. I appreciate you posting them here for me.
Let's make some $$$. Go ELTP.
That is bad news for ELTP....LOL
6 More weeks of this with 6 more weeks of word vomit from the lottery club members.
This is setting up to be a disaster by the next
" greatest CC in company history"
ELTP stock price and the movement tells me how manipulated the stock market can be, especially on the OTC board. For a profitable stock that grows exponentially in revenue and hitting highs on its earnings call only to go DOWN, shows blatant price fixing. Won't be a buyer until .14 range.
.20, .18, .16, .06 Zzzzz
Close. I have 180K shares. Haven't been able to add more lately .................
Of course: I don’t know why this ever surprises me the way they let marketmakers totally control the PPS here they’re not making enough money trough trading with the price of the stock in the volumes to be doing it to actually make money somehow somebody just wants to constantly pound this thing down for what purpose only they know but can’t believe somebody SEC somebody doesn’t get involved look at the valuation look at the revenues and this is what they allow to happen. Oh well, we will have the last laugh on buy out and what the heck Rental condo sells within a month buying a lot more. Take care everyone see how it ends up closing today.
MARKET OPEN TODAY !!!!
API for VyvANCE IS SCARCE. Hope Nasratcan get some with his connections.
ELTP
You do not have to worry - "the King" predicted it would be a slam dunk lol
-------------------
I really hope Vyvanse gets a relatively quick approval. That is a massive opportunity.
Who knows how long Oxy will be jammed up.
Ready to hear when the next big ANDA will start/finish trials and get filed also.
Yahoo fins. already has 64 employees posted for Elite
https://finance.yahoo.com/quote/ELTP/
If they are working a swing shift till the new place is operational then we could see 100 mill. for the fiscal.
Kirko will sell every pill Elite can make
lol you think those 2 people liking his posts are someone else? lolololol hahahhahahahahaha. Bro....stop it.
Is the ANDA already filed for vyvanse? I don't recall seeing the BE study results.
$$eltp$$
Followers
|
968
|
Posters
|
|
Posts (Today)
|
54
|
Posts (Total)
|
403187
|
Created
|
03/24/09
|
Type
|
Free
|
Moderators jimr1717 mrwrn2010 NASDAQ2020 IB_ namtae Dr JoeBarducci |
Senior Moderator: IB_
Posted: 7/02/2024
________________________________________________________________________________________________________________
Elite Pharmaceuticals, Inc. |
Website | Location | Employees | Facility | CEO |
www.elitepharma.com | Northvale, New Jersey | 64 | 85,000 sq ft | Nasrat Hakim |
Products & Pipeline | ||||
Drug | Market Size | Status | Competitors | Marketed By |
Adderall IR | 389.8 M | On Market | 15 | Elite |
Adderall XR | 1.56 B | On Market | 10 | Elite & Prasco |
Dantrolene | 6.3 M | On Market | 2 | Elite |
Isradipine | 5.5 M | On Market | 1 | Elite |
Loxapine | 5 M | On Market | 2 | Elite |
Phendimetrazine | 4.5 M | On Market | 4 | Elite |
Trimipramine | 2 M | On Market | 1 | Elite |
Naltrexone | 16 M | On Market | 5 | Precision Dose |
Phentermine Capsules | 7.5 M | On Market | 6 | Precision Dose |
Phentermine Tablets | 40 M | On Market | 8 | Precision Dose |
Vigabatrin | 233.7 M | On Market | 13 | Pyros |
Doxycycline | 85 M | Approved (Discontinued) | 9 | ---------- |
Tylenol with Codeine | 45 M | Approved | 5 | ---------- |
Dopamine Agonist | 12 M | Filed with FDA - 22 Dec 2022 | ---------- | ---------- |
Methotrexate | 64.3M | Approved - 16 May 2024 | 8 | Elite |
Percocet | 500 M | Approved | --------- | ---------- |
Norco | 477 M | Approved | --------- | ---------- |
Methadone | 30 M | Approved | --------- | ---------- |
OxyContin | 720 M | Filed with FDA - 17 Aug 2023 | ---------- | ---------- |
Vyvanse | 5.1 B | Filed with FDA - 21 Dec 2023 | 14 | ---------- |
Concerta | 1.16 B | In Development (Final Stages) | 9 | ---------- |
Financials | ||||
Fiscal Year | Revenue | Change | Net Income | Change |
2019 | 7,568,508 | ---------- | (9,279,321) | ---------- |
2020 | 17,994,639 | +137.76% | (2,240,351) | +75.86% |
2021 | 25,380,749 | +41.05% | 5,088,421 | +327.13% |
2022 | 32,262,117 | +27.11% | 8,898,245 | +74.87% |
2023 | 34,155,114 | +5.87% | 3,561,846 | -59.97% |
2024 | 56,625,128 | +65.79% | 20,108,631 | +464.56% |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |